[1] 葛均波,徐永健. 内科学[M] . 第8版. 北京:人民卫生出版社,2013:521-545. [2] White H,Sosnowski K,Bird R, et al. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit[J] . Blood Coagul Fibrinolysis, 2012,23(4):304-310. [3] Van PY, Cho SD,Underwood SJ, et al. Thrombelasto-graphy versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients[J] . J Trauma, 2009, 66(6):1509-1515. [4] Al Dieri R, Alban S, Béguin S, et al. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight[J] . J Thromb Haemost, 2006, 4(1):83-89. [5] Kovacs MJ, Kearon C,Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin[J] . Circulation, 2004,110(12):1658-1663. [6] Barras MA, Duffull SB,Atherton JJ, et al. Individualized compared with conventional dosing of enoxaparin[J] . Clin Pharmacol Ther, 2008, 83(6):882-888. [7] Reinhfer M, Brauer M, Franke U, et al. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass[J] . Blood Coagul Fibrinolysis, 2008, 19(3):212-219. |